Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="left">REDWOOD CITY, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) — Seer (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today that it has signed a non-exclusive commercial agreement…

This post was originally published on this site